Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study

References

• Golbus J, McCune WJ. Lupus nephritis. Classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am. 1994;20:213–42.
   PubMed Web of Science ®Google Scholar
• Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol. 2011;7:96–109.
   PubMed Web of Science ®Google Scholar
• Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–9.
   PubMed Web of Science ®Google Scholar
• Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248–57.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.
   PubMed Web of Science ®Google Scholar
• Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyap-orn P, Thakkinstian A. Efficacy and adverse events of myco-phenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medi-cine (Baltimore). 2010;89:227–35.
   Google Scholar
• Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67:195–205.
   Google Scholar
• Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49:128–40.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythe-matosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241–50.
   PubMed Web of Science ®Google Scholar
• Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18: 257–63.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630–40.
   Google Scholar
• Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13: 176–81.
   Google Scholar
• Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of ta-crolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol. 2009;19:606–15.
   Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed, Ede R, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophospha-mide. Arthritis Rheum. 2002;46:2121–31.
   Google Scholar
• Matsuyama N, Morimoto S, Tokano Y, Amano H, Nozawa K, Isonuma H, et al. The long-term prognosis of lupus nephritis patients treated with intravenous cyclophosphamide. Intern Med. 2010;49:823–8.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Hirose S, Tanabe N, Sato H, Nakatsue T, Ajiro J, et al. Mizoribine therapy for patients with lupus nephritis: the associ-ation between peak mizoribine concentration and clinical effi-cacy. Mod Rheumatol. 2007;17:206–12.
   PubMedGoogle Scholar
• Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, et al. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol. 2007;17:92–7.
   PubMedGoogle Scholar
• Suzuki D, Ogawa N, Sawada J, Kimoto O, Shimoyama K, Hayashi H. The efficacy of mycophenolate mofetil for systemic lupus erythematosus. Nihon Rinsho Meneki Gakkai Kaishi. 2009;32:263-8 (in Japanese).
   Google Scholar
• Mohan S, Radhakrishnan J. Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy. Clin Nephrol. 2011;75:233–41.
   PubMed Web of Science ®Google Scholar
• Han S, Kim-Howard X, Deshmukh H, Kamatani Y, Viswanathan P, Guthridge JM, et al. Evaluation of imputation-based associa-tion in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythema-tosus (SLE). Hum Mol Genet. 2009;18:1171–80.
   PubMed Web of Science ®Google Scholar
• Yang W, Zhao M, Hirankam N, Lau CS, Mok CC, Chan TM, et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum Mol Genet. 2009;18:2063–70.
   PubMed Web of Science ®Google Scholar
• Arahata H, Migita K, Izumoto H, Miyashita T, Munakata H, Nakamura H, et al. Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intrave-nous immunoglobulins. Clin Rheumatol. 1999;18:77–81.
   PubMed Web of Science ®Google Scholar
• Morimoto S, Watanabe T, Lee S, Amano H, Kanamaru Y, Ohsawa I, et al. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus. Mod Rheu-matol. 2010;20:291–4.
   PubMed Web of Science ®Google Scholar
• Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH. Chico-pathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int. 2009;76:307–17.
   PubMed Web of Science ®Google Scholar
• Yu F, Tan Y, Wu LH, Zhu SN, Liu G, Zhao MH. Class IV-G and IV-S lupus nephritis in Chinese patients: a large cohort study from a single center. Lupus. 2009;18:1073–81.
   PubMed Web of Science ®Google Scholar